The median progression-free of charge survival times were 8.9 months with cetuximab plus FOLFIRI and 8.0 months with FOLFIRI alone. The adjusted hazard ratio for death with cetuximab plus FOLFIRI was 0.93 . Median general survival times were 19.six months in the FOLFIRI group . Confirmed full or partial tumor responses occurred in 281 sufferers receiving cetuximab plus FOLFIRI and in 232 sufferers receiving FOLFIRI alone.40 .0 percent vs. 3.7 percent), while was the rate of R0 resection with curative intent before disease progression . Subgroup Analysis Relating to KRAS Mutation Position Tumor samples obtained in baseline from 540 individuals were ideal for the evaluation of KRAS mutation position; samples from the rest of the patients had been either of insufficient size or unavailable.Kaiser Health News: Advocates Urge More Authorities Oversight Of Medicaid Managed Care When the federal government recently gave Florida the green light to vastly broaden its experiment with privatizing Medicaid, patient advocates raised an alarm. They cited serious problems with the state's five-county pilot managed care plan and urged close monitoring of the firms that run private Medicaid plans to ensure that they don't scrimp on care . Related StoriesICD-10 Clinical Modification: an interview with Dr. Jon Elion, Founder, ChartWise Medical SystemsReducing hospital readmissions through Transitional Treatment: an interview with Rani Khetarpal Philadelphia Inquirer: How Baby Erik Got Insurance Two times after Erik Friedman was born, his parents applied for coverage under Pennsylvania's universal Children's Health Insurance Program.